Skip to main content
. 2017 Jan 16;3:16046. doi: 10.1038/cddiscovery.2016.46

Figure 4.

Figure 4

Monovalent IAP antagonists and linker chain-extended bivalent analog B3-EL4 were less efficient at inducing the degradation of TRAF2-associated cIAP1. (a) The whole-cell lysates of EVSA-T cells prepared in Figure 3 were subjected to co-IP using anti-TRAF2 antibody. The IP complex was evaluated by the western blot analysis with anti-cIAP1 antibody. Representative result from two independent experiments. (b) Comparison between B1 and M4 in degrading TRAF2-associated cIAP1 in EVSA-T cells. M4 treatment resulted in higher residual levels of TRAF2-associated cIAP1 than B1 treatment throughout the time points investigated. Representative result from two independent experiments. (c) SK-OV-3 cells were incubated in the presence or absence of 300 nmol/l of IAP antagonist for 4 h. Whole-cell lysates were subjected to IP using anti-TRAF2 antibody. The IP complex was evaluated by the western blot analysis with anti-cIAP1 antibody. Representative result from two independent experiments.